A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)

Non-small cell lung cancer

1. Progression-free survival (PFS), 2. Overall survival (OS)

1. Objective response rate (ORR), 2. Duration of response (DOR), 3. Number of participants who experience one or more Adverse Events (AEs), 4. Number of participants who discontinue study treatment due to an AE, 5. Change from baseline in global health status/quality of life (items 29 and 30) score, on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30), 6. Change from baseline in the physical functioning (items 1-5) score, on the EORTC QLQ-C30, 7. Change from baseline in the role functioning (items 6-7) score, on the EORTC QLQ-C30, 8. Change from baseline in the dyspnea (item 8) score, on the EORTC QLQ-C30, 9. Change from baseline in the cough (item 31) score, on the EORTC QLQ- LC13, 10. Change from baseline in the chest pain (item 40) score, on the EORTC QLQ-LC13, 11. Time to deterioration (TTD) in global health status/quality of life (items 29 and 30) score, on the EORTC-QLQ-C30, 12. TTD in the physical functioning (items 1-5) score, on the EORTC-QLQ-C30, 13. TTD in the role functioning (items 6-7) score, on the EORTC QLQ-C30, 14. TTD in the dyspnea (item 8) score, on the EORTC QLQ-C30, 15. TTD in the cough (item 31) score, on the EORTC QLQ-Lung Cancer version (LC13), 16. TTD in the chest pain (item 40) score, on the EORTC QLQ-LC13

No related papers found yet.

Austria, Bulgaria, France, Germany, Greece, Italy, Netherlands, Poland, Romania, Spain